AZD2014-Vistusertib_PI3K/Akt/mTOR 信号通路-MedChemExpress LLC

联系我们时请说明是91化工仪器网上看到的信息，谢谢!

产品简介 品牌 MedChemExpress (MCE) 货号 HY-15247 规格 10 mM * 1 mL；2 mg；5 mg；10 mg；50 mg；100 m 供货周期 现货 应用领域 生物产业     Vistusertib （AZD2014） 是一种ATP竞争性的 mTOR 抑制剂，IC50 为 2.81 nM。AZD2014 抑制 mTORC1 和 mTORC2 复合物。
详细介绍 Vistusertib

产品活性：Vistusertib (AZD2014) 是一种ATP竞争性的 mTOR 抑制剂，IC50 为 2.81 nM。AZD2014 抑制 mTORC1 和 mTORC2 复合物。

研究领域：PI3K/Akt/mTOR | Autophagy

作用靶点：mTOR | Autophagy

In Vitro: The inhibitory effects of Vistusertib (AZD2014) are measured against isolated recombinant mTOR enzyme (IC50 of 2.81 nM) as well as in cellular assays measuring both mTORC1 and mTORC2 activities. In MDAMB468 cells, Vistusertib (AZD2014) decreases the phosphorylation of the mTORC1 substrate ribosomal protein S6 (Ser235/236) with a mean IC50 value of 210 nM and the mTORC2 substrate AKT (Ser473) with a mean IC50 value of 78 nM.

In Vivo: Vistusertib (AZD2014) induces dose-dependent tumor growth inhibition in several xenograft and primary explant models. The antitumor activity of Vistusertib (AZD2014) is associated with modulation of both mTORC1 and mTORC2 substrates, consistent with its mechanism of action. The pharmacokinetics of Vistusertib (AZD2014) in mice is tested upon administration of doses between 7.5 and 15 mg/kg. A dose-dependent increase in Cmax and AUC is observed following single dose and repeat dosing of AZD2014: Cmax range from 1 to 16 μM and AUC range from 220 to 5,042 μM·h across this dose range. The pharmacodynamic effect of Vistusertib (AZD2014) against an mTORC1 biomarker (phosphorylation of S6) and an mTORC2 biomarker (phosphorylation of AKT) is assessed in SCID mice bearing MCF7 xenografts following administration of 3.75, 7.5, and 15 mg/kg AZD2014. There is a good relationship between the drug plasma concentrations and biomarker levels (estimated p-AKT IC50 of 0.119 μM total, 53% SE, and estimated p-S6 IC50 0.392 μM, 28.8% SE).

相关产品：Drug Repurposing Compound Library | Anti-Aging Compound Library | Kinase Inhibitor Library | Clinical Compound Library | Clinical Compound Library Plus | PI3K/Akt/mTOR Compound Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library Plus | Bioactive Compound Library Plus | Autophagy Compound Library | Rapamycin | Everolimus | Torin 1 | MHY1485 | AZD-8055 | Sapanisertib | Dactolisib | LY3023414 | Temsirolimus | Torin 2 | Torkinib | Salidroside | PF-04691502 | Omipalisib | PI-103 | Bimiralisib | OSI-027 | Dihydromyricetin | 3BDO | Gedatolisib | Apitolisib | Voxtalisib | KU-0063794 | Deforolimus | CC-115 | GDC-0084 | PP121 | CC-223

以上信息由企业自行提供，信息内容的真实性、准确性和合法性由相关企业负责，91化工仪器网对此不承担任何保证责任。
温馨提示：为规避购买风险，建议您在购买产品前务必确认供应商资质及产品质量。 搜本商铺 或 搜全站

MedChemExpress LLC - 主营产品： 西罗莫司 Rapamycin,瑞沙托维 TAK-242,奥拉帕尼 Olaparib

地址：上海市浦东新区张衡路1999弄3号楼      联系电话：86-021-58955995      手机：18019480960     传真：86-021-53700325
91化工仪器网 设计制作，未经允许翻录必究 .      Copyright(C) http://www.chem17.com,      All rights reserved. 以上信息由企业自行提供，信息内容的真实性、准确性和合法性由相关企业负责，91化工仪器网对此不承担任何保证责任。
温馨提示：为规避购买风险，建议您在购买产品前务必确认供应商资质及产品质量。
会员登录